FDA approval summary: palbociclib for male patients with metastatic breast cancer

S Wedam, L Fashoyin-Aje, E Bloomquist, S Tang… - Clinical Cancer …, 2020 - AACR
Abstract On April 4, 2019, the FDA approved a supplemental new drug application for
palbociclib (IBRANCE), to expand the approved indications in women with hormone …

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer

S Khozin, RA Miksad, J Adami, M Boyd, NR Brown… - Cancer, 2019 - Wiley Online Library
Background Despite the rapid adoption of immunotherapies in advanced non–small cell
lung cancer (advNSCLC), knowledge gaps remain about their real‐world (rw) performance …

[HTML][HTML] Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored …

SD Griffith, M Tucker, B Bowser, G Calkins, C Chang… - Advances in …, 2019 - Springer
Introduction Real-world evidence derived from electronic health records (EHRs) is
increasingly recognized as a supplement to evidence generated from traditional clinical …

Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non–small …

SD Griffith, RA Miksad, G Calkins, P You… - JCO clinical cancer …, 2019 - ascopubs.org
PURPOSE Large, generalizable real-world data can enhance traditional clinical trial results.
The current study evaluates reliability, clinical relevance, and large-scale feasibility for a …

Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers

RB Parikh, EJ Min, EP Wileyto, F Riaz, CP Gross… - JAMA …, 2021 - jamanetwork.com
Importance Immune checkpoint inhibitors (ICIs) are part of standard of care for patients with
many advanced solid tumors. Patients with poor performance status or organ dysfunction …

Moving beyond static survivorship care plans: A systems engineering approach to population health management for cancer survivors

AJ Tevaarwerk, JR Klemp, GJ van Londen, BW Hesse… - Cancer, 2018 - Wiley Online Library
The American cancer survivor population is ever‐growing, with necessary follow‐up
primarily accomplished in a high‐touch fashion—adding to unsustainability and …

[HTML][HTML] Immunotherapy treatment patterns and outcomes among ALK-positive patients with non–small-cell lung cancer

M Jahanzeb, HM Lin, X Pan, Y Yin, P Baumann… - Clinical lung cancer, 2021 - Elsevier
Introduction The treatment landscape for anaplastic lymphoma kinase (ALK)-positive non–
small-cell lung cancer (NSCLC) primarily involves ALK-directed tyrosine kinase inhibitors …

Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer

E Feld, J Harton, NJ Meropol, BJS Adamson, A Cohen… - European urology, 2019 - Elsevier
Background Limited data compare first-line carboplatin-based chemotherapy and immune
checkpoint blockade in cisplatin-ineligible metastatic urothelial carcinoma (mUC) patients …

Treatment patterns and overall survival in metastatic urothelial carcinoma in a real-world, US setting

JC Simeone, BL Nordstrom, K Patel, H Mann… - Cancer …, 2019 - Elsevier
Background Metastatic urothelial carcinoma (mUC) treated with chemotherapy is associated
with poor survival; however, as the field of immuno-oncology continues to evolve, new …

[HTML][HTML] Estimating redundancy in clinical text

T Searle, Z Ibrahim, J Teo, R Dobson - Journal of biomedical informatics, 2021 - Elsevier
The current mode of use of Electronic Health Records (EHR) elicits text redundancy.
Clinicians often populate new documents by duplicating existing notes, then updating …